Yousif Capital Management LLC Decreases Position in Edwards Lifesciences Co. (NYSE:EW)

Yousif Capital Management LLC decreased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 6.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 87,633 shares of the medical research company’s stock after selling 6,314 shares during the quarter. Yousif Capital Management LLC’s holdings in Edwards Lifesciences were worth $6,487,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in EW. Wellington Management Group LLP boosted its position in shares of Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after buying an additional 14,610,123 shares during the last quarter. Jennison Associates LLC bought a new position in Edwards Lifesciences during the 4th quarter valued at about $555,939,000. Assenagon Asset Management S.A. boosted its holdings in shares of Edwards Lifesciences by 475.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after acquiring an additional 3,506,886 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Edwards Lifesciences by 239.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after acquiring an additional 2,606,950 shares during the period. Finally, Seilern Investment Management Ltd purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $109,490,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 1.6 %

EW stock opened at $70.96 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The business has a 50 day simple moving average of $72.49 and a two-hundred day simple moving average of $69.54. The company has a market capitalization of $41.85 billion, a price-to-earnings ratio of 10.24, a PEG ratio of 3.72 and a beta of 1.10.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,000 shares of company stock worth $547,430. 1.29% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Morgan Stanley restated an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a report on Friday, October 11th. Citigroup lifted their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Canaccord Genuity Group increased their target price on Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a report on Thursday, December 5th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Finally, Robert W. Baird lowered their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $79.19.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.